{
  "hash": "d2456fc21d1838bba1127b270e031ccf",
  "result": {
    "markdown": "---\ntitle: \"Systematic review and meta-analysis of Real-World Evidence\"\nauthors:   \n  - name: Dimitris Mavridis\n    affiliations:\n      - ref: ioannina\n  - name: Thomas Debray\n    orcid: 0000-0002-1790-2719\n    affiliations:\n      - ref: smartdas\naffiliations:\n  - id: smartdas\n    name: Smart Data Analysis and Statistics B.V.\n    city: Utrecht\n  - id: ioannina\n    name: University of Ioannina\n    city: Ioannina\nformat:\n  html:\n    toc: true\n    number-sections: true\nexecute:\n  cache: true\nbibliography: 'https://api.citedrive.com/bib/0d25b38b-db8f-43c4-b934-f4e2f3bd655a/references.bib?x=eyJpZCI6ICIwZDI1YjM4Yi1kYjhmLTQzYzQtYjkzNC1mNGUyZjNiZDY1NWEiLCAidXNlciI6ICIyNTA2IiwgInNpZ25hdHVyZSI6ICI0MGFkYjZhMzYyYWE5Y2U0MjQ2NWE2ZTQzNjlhMWY3NTk5MzhhNzUxZDNjYWIxNDlmYjM4NDgwOTYzMzY5YzFlIn0=/bibliography.bib'\n---\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-1_33471f01363a71bc5e0e9aa7a0316d9c'}\n\n:::\n\n\n\n## Introduction\n\nWe first load the required packages\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-2_9bc7a3a3d58becc2831348d344f1817e'}\n\n```{.r .cell-code}\nlibrary(dplyr)\nlibrary(gemtc)\nlibrary(netmeta)\n```\n:::\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-3_a86b4f8133444f5a232a603c773f1d8b'}\n\n:::\n\n\n\n## Pairwise meta-analysis of clinical trials\n\n### Toculizumab for coronavirus disease 2019\nIn this example, we consider the results from a systematic literature review of clinical trials investigating any pharmacological in hosptialized patients with coronavirus disease 2019 [@selvarajan_efficacy_2022]. A total of 23 randomized controlled trials were included and studied seven different interventions: dexamethasone, remdesivir, tocilizumab, hydroxychloroquine, combination of lopinavir/ritonavir, favipiravir and interferon-β. We here focus on the synthesis of 7 trials that comparted toculizumab (`TOCI`) to standard care (`STD`)\nand collected mortality data. \n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-4_e157bfac9a4ad56633285438029c1202'}\n\n:::\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-5_f0a214bfe2feaa8e19f8777fbc933da0'}\n::: {.cell-output-display}\n\\begin{longtable}{lrrrrrr}\n\\toprule\nstudlab & treat1 & treat2 & event1 & n1 & event2 & n2\\\\\n\\midrule\n\\endfirsthead\n\\multicolumn{7}{@{}l}{\\textit{(continued)}}\\\\\n\\toprule\nstudlab & treat1 & treat2 & event1 & n1 & event2 & n2\\\\\n\\midrule\n\\endhead\n\n\\endfoot\n\\bottomrule\n\\endlastfoot\nHermine et al & TOCI & STD & 7 & 63 & 8 & 67\\\\\nRosas et al & TOCI & STD & 58 & 294 & 28 & 144\\\\\nSalama et al & TOCI & STD & 26 & 249 & 11 & 128\\\\\nSalvarini et al & TOCI & STD & 2 & 60 & 1 & 66\\\\\nStone et al & TOCI & STD & 9 & 161 & 3 & 82\\\\\nVeiga et al & TOCI & STD & 14 & 65 & 6 & 64\\\\*\n\\end{longtable}\n:::\n:::\n\n\n\nWe now conduct a pairwise meta-analysis to assess the pooled effect of tocilizumab versus standard care. For each study, the log odds ratio and corresponding standard error is derived after which the corresponding estimates are pooled using the  Mantel-Haenszel method.\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-6_303e9c2b50d4a1c51ba9bf5fcaaefb4d'}\n\n```{.r .cell-code}\nresults.TOCI <- metabin(event1,n1,event2,n2,studlab,data=tocilizumab,\n                        sm=\"OR\",main=\"tocilizumab vs standard care\", \n                        prediction=TRUE)\nforest(results.TOCI, leftcols = \"studlab\", rightcols = \"effect.ci\")\n```\n\n::: {.cell-output-display}\n![](chapter_10_files/figure-pdf/unnamed-chunk-6-1.pdf){fig-pos='H'}\n:::\n:::\n\n\n\nAltough a random effects meta-analysis was conducted, no heterogeneity was found ($\\tau$=0, with a 95\\% confidence interval ranging from 0 to 0.85).\n\n\n### Remdesivir for coronavirus disease 2019\nIn aforementioned example, a total of 4 trials compared remdesivir to standard care:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-7_7ee1384b1fa97c48fb7b9163193dabf5'}\n::: {.cell-output-display}\n![](chapter_10_files/figure-pdf/unnamed-chunk-7-1.pdf)\n:::\n:::\n\n\n\n\n## Network meta-analysis of clinical trials\n\nWe here use the R packages `netmeta` for conducting a frequentist network meta-analysis. A detailed tutorial on the use of  `netmeta` is available from the book [Doing Meta-Analysis with R: A Hands-On Guide](https://bookdown.org/MathiasHarrer/Doing_Meta_Analysis_in_R/).\n\n\n\n### Interventions for coronavirus disease 2019\nWe here consider data from a study which aimed to assess the comparative effectiveness of remdesivir and tocilizumab for reducing mortality in hospitalised COVID-19 patients. 80 trials were identified from two published network meta-analyses [@selvarajan_efficacy_2022], [@Siemieniuk_2020], a living COVID-19 trial database (COVID-NMA Initiative) [Covid-NMA.com], and a clinical trial database [clinicaltrials.gov]. Trials were included in this study if the patient population included hospitalized COVID-19 patients, active treatment was remdesivir or tocilizumab, comparator treatment was placebo or standard care, short-term mortality data was available, and the trial was published. 21 trials were included. For included trials, a risk of bias score was extracted from the COVID-NMA Initiative.\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-8_903b91b67465c23a6f1f9f38da38bf1c'}\n::: {.cell-output-display}\n\\begin{longtable}{lrrrrrr}\n\\toprule\nstudlab & treat1 & treat2 & event1 & n1 & event2 & n2\\\\\n\\midrule\n\\endfirsthead\n\\multicolumn{7}{@{}l}{\\textit{(continued)}}\\\\\n\\toprule\nstudlab & treat1 & treat2 & event1 & n1 & event2 & n2\\\\\n\\midrule\n\\endhead\n\n\\endfoot\n\\bottomrule\n\\endlastfoot\nAder & REM & STD & 34 & 414 & 37 & 418\\\\\nBeigel (ACTT-1) & REM & STD & 59 & 541 & 77 & 521\\\\\nBroman & TOCI & STD & 1 & 57 & 0 & 29\\\\\nCriner & REM & STD & 4 & 384 & 4 & 200\\\\\nDeclerq (COV-AID) & TOCI & STD & 10 & 81 & 9 & 74\\\\\nGordon (REMAP-CAP) & TOCI & STD & 83 & 353 & 116 & 358\\\\\nHermine (CORIMUNO) & TOCI & STD & 7 & 63 & 8 & 67\\\\\nHorby (RECOVERY) & TOCI & STD & 621 & 2022 & 729 & 2094\\\\\nIslam & REM & STD & 0 & 30 & 0 & 30\\\\\nMahajan & REM & STD & 5 & 34 & 3 & 36\\\\\nPan (WHO Solidarity) & REM & STD & 602 & 4146 & 643 & 4129\\\\\nRosas (COVACTA) & TOCI & STD & 58 & 294 & 28 & 144\\\\\nRutgers & TOCI & STD & 21 & 174 & 34 & 180\\\\\nSalama (EMPACTA) & TOCI & STD & 26 & 249 & 11 & 128\\\\\nSalvarani & TOCI & STD & 2 & 60 & 1 & 63\\\\\nSoin (COVINTOC) & TOCI & STD & 11 & 92 & 15 & 88\\\\\nSpinner & REM & STD & 5 & 384 & 4 & 200\\\\\nStone (BACC-BAY) & TOCI & STD & 9 & 161 & 4 & 82\\\\\nTalaschian & TOCI & STD & 5 & 17 & 4 & 19\\\\\nVeiga (TOCIBRAS) & TOCI & STD & 14 & 65 & 6 & 64\\\\\nWang & REM & STD & 22 & 158 & 10 & 78\\\\*\n\\end{longtable}\n:::\n:::\n\n\n\nThe corresponding network is displayed below:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-9_f805bca69c26141a5bbf4686cf417b30'}\n::: {.cell-output-display}\n![Evidence network of the 21 coronavirus-19 trials](chapter_10_files/figure-pdf/unnamed-chunk-9-1.pdf)\n:::\n:::\n\n\n\nWe use the following command to calculate the log odds ratios and corresponding standard errors for each study:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-10_7f861c2cb618341f864bf69c54d17a9f'}\n\n```{.r .cell-code}\ncovid <- pairwise(treat = treat, event = event, n = n, studlab = studlab, sm = \"OR\")\nhead(covid)\n```\n:::\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-11_a61e9e4e6531b232dc21ea35a730e18d'}\n::: {.cell-output-display}\n\\begin{tabular}{r|r|l|l|l|r|r|r|r|r|l}\n\\hline\nTE & seTE & studlab & treat1 & treat2 & event1 & n1 & event2 & n2 & incr & allstudies\\\\\n\\hline\n-0.0819293 & 0.2483849 & Ader & REM & STD & 34 & 414 & 37 & 418 & 0.0 & FALSE\\\\\n\\hline\n-0.3483875 & 0.1851030 & Beigel (ACTT-1) & REM & STD & 59 & 541 & 77 & 521 & 0.0 & FALSE\\\\\n\\hline\n0.4487619 & 1.6487159 & Broman & TOCI & STD & 1 & 57 & 0 & 29 & 0.5 & FALSE\\\\\n\\hline\n-0.6620566 & 0.7125543 & Criner & REM & STD & 4 & 384 & 4 & 200 & 0.0 & FALSE\\\\\n\\hline\n0.0170679 & 0.4904898 & Declerq (COV-AID) & TOCI & STD & 10 & 81 & 9 & 74 & 0.0 & FALSE\\\\\n\\hline\n-0.4442338 & 0.1688337 & Gordon (REMAP-CAP) & TOCI & STD & 83 & 353 & 116 & 358 & 0.0 & FALSE\\\\\n\\hline\n\\end{tabular}\n:::\n:::\n\n\n\nBelow, we conduct a random effects network meta-analysis where we consider \nstandard care (`STD`) as the control treatment. Note that we have one study where \nzero cell counts occur, this study will not contribute to the NMA as the log odds \nratio and its standard error cannot be determined.\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-12_59f419ad273a97a46ba6b11d1b6351d6'}\n\n```{.r .cell-code}\nNMA.covid <- netmeta(TE = TE, seTE = seTE, treat1 = treat1, treat2 = treat2,\n                     studlab = studlab, data = covid, sm = \"OR\", ref = \"STD\",\n                     comb.random = TRUE, common = FALSE, warn = FALSE)\nNMA.covid \n```\n\n::: {.cell-output .cell-output-stdout}\n```\nNumber of studies: k = 20\nNumber of pairwise comparisons: m = 20\nNumber of treatments: n = 3\nNumber of designs: d = 2\n\nRandom effects model\n\nTreatment estimate (sm = 'OR', comparison: other treatments vs 'STD'):\n         OR           95%-CI     z p-value\nREM  0.8999 [0.8067; 1.0039] -1.89  0.0588\nSTD       .                .     .       .\nTOCI 0.8301 [0.7434; 0.9268] -3.31  0.0009\n\nQuantifying heterogeneity / inconsistency:\ntau^2 = 0; tau = 0; I^2 = 0% [0.0%; 48.9%]\n\nTests of heterogeneity (within designs) and inconsistency (between designs):\n                    Q d.f. p-value\nTotal           16.38   18  0.5663\nWithin designs  16.38   18  0.5663\nBetween designs  0.00    0      --\n```\n:::\n:::\n\n\n\nA league table of the treatment effect estimates is given below:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-13_e47684c20fd1f35c30ac459ba3b8a4c2'}\n\n```{.r .cell-code}\nnetleague(NMA.covid)\n```\n\n::: {.cell-output .cell-output-stdout}\n```\nLeague table (random effects model):\n                                                                        \n                     REM 0.8999 [0.8067; 1.0039]                       .\n 0.8999 [0.8067; 1.0039]                     STD 1.2047 [1.0789; 1.3451]\n 1.0842 [0.9282; 1.2663] 1.2047 [1.0789; 1.3451]                    TOCI\n```\n:::\n:::\n\n\n\nWe can also present the results in a forest plot:\n  \n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-14_0c8d057897886dc789a5118dcbbca4f2'}\n::: {.cell-output-display}\n![](chapter_10_files/figure-pdf/unnamed-chunk-14-1.pdf)\n:::\n:::\n\n\n\nThe figure below shows the percentage of direct and indirect evidence used for each estimated comparison. \n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-15_cbf0badc2ba2beb196f072968509e2d1'}\n::: {.cell-output-display}\n![](chapter_10_files/figure-pdf/unnamed-chunk-15-1.pdf)\n:::\n:::\n\n\n\nWe now consider a Bayesian random effects network meta-analysis that analyzes the observed event counts\nusing a binomial link function. \n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-16_329120f2eb5df877c505abf19073fe95'}\n\n```{.r .cell-code}\nbdata <- data.frame(study = studlab,\n                    treatment = treat,\n                    responders = event,\n                    sampleSize = n)\n\nnetwork <- mtc.network(data.ab  = bdata)\n\nmodel <- mtc.model(network,\n                   likelihood = \"binom\",\n                   link = \"log\",\n                   linearModel = \"random\",\n                   n.chain = 3)\n```\n:::\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-17_bb47f955ef2e7fec1ade18135c55996a'}\n\n```{.r .cell-code}\n# Adaptation\nmcmc1 <- mtc.run(model, n.adapt = 1000, n.iter = 1000, thin = 10)\n```\n\n::: {.cell-output .cell-output-stdout}\n```\nCompiling model graph\n   Resolving undeclared variables\n   Allocating nodes\nGraph information:\n   Observed stochastic nodes: 42\n   Unobserved stochastic nodes: 45\n   Total graph size: 930\n\nInitializing model\n```\n:::\n\n```{.r .cell-code}\n# Sampling\nmcmc2 <- mtc.run(model, n.adapt = 10000, n.iter = 100000, thin = 10)\n```\n\n::: {.cell-output .cell-output-stdout}\n```\nCompiling model graph\n   Resolving undeclared variables\n   Allocating nodes\nGraph information:\n   Observed stochastic nodes: 42\n   Unobserved stochastic nodes: 45\n   Total graph size: 930\n\nInitializing model\n```\n:::\n:::\n\n\n\nWe can extract the pooled treatment effect estimates from the posterior distribution. When using `STD` as control group, we have:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-18_f0e3fa86d34d84f897b1aa547bceaf4f'}\n\n```{.r .cell-code}\nsummary(relative.effect(mcmc2, t1 = \"STD\"))\n```\n\n::: {.cell-output .cell-output-stdout}\n```\n\nResults on the Log Risk Ratio scale\n\nIterations = 10010:110000\nThinning interval = 10 \nNumber of chains = 3 \nSample size per chain = 10000 \n\n1. Empirical mean and standard deviation for each variable,\n   plus standard error of the mean:\n\n              Mean      SD  Naive SE Time-series SE\nd.STD.REM  -0.1083 0.09805 0.0005661      0.0008072\nd.STD.TOCI -0.1109 0.08315 0.0004800      0.0008498\nsd.d        0.1134 0.08883 0.0005129      0.0018761\n\n2. Quantiles for each variable:\n\n               2.5%      25%      50%      75%   97.5%\nd.STD.REM  -0.31694 -0.16154 -0.10534 -0.05205 0.08566\nd.STD.TOCI -0.25663 -0.16159 -0.11886 -0.06907 0.08273\nsd.d        0.00275  0.04497  0.09498  0.16190 0.33112\n```\n:::\n:::\n\n\n\nThe corresponding odds ratios are as follows:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-19_f13bc803bb368a81b520c4d4234e41a8'}\n::: {.cell-output-display}\n\\begin{longtable}{lc}\n\\toprule\nComparison & 95\\% CrI\\\\\n\\midrule\nREM vs. STD & 0.9 (0.73; 1.09)\\\\\nTOCI vs. STD & 0.89 (0.77; 1.09)\\\\\nREM vs. TOCI & 1.01 (0.74; 1.27)\\\\\n\\bottomrule\n\\end{longtable}\n:::\n:::\n\n\n\nFinally, we expand the COVID-19 network with trials investigating the effectiveness of hydroxychloroquine (HCQ), lopinavir/ritonavir (LOPI), dexamethasone (DEXA) or interferon-$\\beta$ (INTB) [@selvarajan_efficacy_2022]. The corresponding network is displayed below:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-20_e3da83b268793442a5f48325d25a8682'}\n::: {.cell-output-display}\n![Evidence network of the 33 coronavirus-19 trials](chapter_10_files/figure-pdf/unnamed-chunk-20-1.pdf)\n:::\n:::\n\n\n\n\nWe conducted a random effects network meta-analysis, results are depicted below:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-21_5f9959e108a6b4f4a5c61d2791034a88'}\n::: {.cell-output .cell-output-stdout}\n```\nNumber of studies: k = 33\nNumber of pairwise comparisons: m = 33\nNumber of treatments: n = 7\nNumber of designs: d = 6\n\nRandom effects model\n\nTreatment estimate (sm = 'OR', comparison: other treatments vs 'STD'):\n         OR           95%-CI     z p-value            95%-PI\nDEXA 0.8557 [0.7558; 0.9688] -2.46  0.0139  [0.7463; 0.9812]\nHCQ  1.1809 [0.8934; 1.5610]  1.17  0.2428  [0.8786; 1.5872]\nINTB 1.1606 [0.9732; 1.3841]  1.66  0.0973  [0.9604; 1.4026]\nLOPI 1.0072 [0.8906; 1.1392]  0.11  0.9085  [0.8794; 1.1537]\nREM  0.8983 [0.8014; 1.0070] -1.84  0.0658  [0.7913; 1.0199]\nSTD       .                .     .       .                 .\nTOCI 0.8304 [0.7410; 0.9306] -3.20  0.0014  [0.7316; 0.9426]\n\nQuantifying heterogeneity / inconsistency:\ntau^2 = 0.0004; tau = 0.0205; I^2 = 0.6% [0.0%; 42.3%]\n\nTests of heterogeneity (within designs) and inconsistency (between designs):\n                    Q d.f. p-value\nTotal           27.18   27  0.4543\nWithin designs  27.18   27  0.4543\nBetween designs  0.00    0      --\n```\n:::\n:::\n\n\n\nWe can calculate the P score for each treatment as follows:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-22_f52f3bd48acbc1378bb320600841d119'}\n\n```{.r .cell-code}\nnetrank(NMA.covidf)\n```\n\n::: {.cell-output .cell-output-stdout}\n```\n     P-score\nTOCI  0.9070\nDEXA  0.8357\nREM   0.7143\nSTD   0.4027\nLOPI  0.3899\nHCQ   0.1336\nINTB  0.1166\n```\n:::\n:::\n\n\n\n\n### Pharmacologic treatments for chronic obstructive pulmonary disease \nIn this example, we consider the resuls from a systematic review of randomized controlled trials on pharmacologic treatments for chronic obstructive pulmonary disease [@Baker_2009]. The primary outcome, occurrence of one or more episodes of COPD exacerbation, is binary (yes / no). For this outcome, five drug treatments (fluticasone, budesonide, salmeterol, formoterol, tiotropium) and two combinations (fluticasone + salmeterol, budesonide + formoterol) were compared to placebo. The authors considered the two combinations as separate treatments instead of evaluating the individual components.\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-23_2b9b1843e37a0835f87247fe1df26099'}\n\n```{.r .cell-code}\ndata(Baker2009)\n```\n:::\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-24_28d19a6613bc62f917e9bff4812ed650'}\n::: {.cell-output-display}\n\\begin{tabular}{l|r|r|l|r|r}\n\\hline\nstudy & year & id & treatment & exac & total\\\\\n\\hline\nLlewellyn-Jones 1996 & 1996 & 1 & Fluticasone & 0 & 8\\\\\n\\hline\nLlewellyn-Jones 1996 & 1996 & 1 & Placebo & 3 & 8\\\\\n\\hline\nBoyd 1997 & 1997 & 2 & Salmeterol & 47 & 229\\\\\n\\hline\nBoyd 1997 & 1997 & 2 & Placebo & 59 & 227\\\\\n\\hline\nPaggiaro 1998 & 1998 & 3 & Fluticasone & 45 & 142\\\\\n\\hline\nPaggiaro 1998 & 1998 & 3 & Placebo & 51 & 139\\\\\n\\hline\n\\end{tabular}\n:::\n:::\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-25_9f9a53c8b04362547d145f13f22a7a81'}\n\n```{.r .cell-code}\nBaker <- pairwise(treat = treatment,\n                  event = exac,\n                  n = total,\n                  studlab = id,\n                  sm = \"OR\",\n                  data = Baker2009)\n\nNMA.COPD <- netmeta(TE = TE, seTE = seTE, treat1 = treat1, treat2 = treat2,\n                    studlab = studlab, data = Baker, sm=\"OR\", ref = \"Placebo\",\n                    comb.random = TRUE)\n```\n\n::: {.cell-output .cell-output-stderr}\n```\nWarning: Comparisons with missing TE / seTE or zero seTE not considered in\nnetwork meta-analysis.\n```\n:::\n\n::: {.cell-output .cell-output-stdout}\n```\nComparisons not considered in network meta-analysis:\n studlab                 treat1     treat2 TE seTE\n      39 Fluticasone+Salmeterol    Placebo NA   NA\n      39 Fluticasone+Salmeterol Salmeterol NA   NA\n      39             Salmeterol    Placebo NA   NA\n```\n:::\n\n```{.r .cell-code}\nnetgraph(NMA.COPD)\n```\n\n::: {.cell-output-display}\n![](chapter_10_files/figure-pdf/unnamed-chunk-25-1.pdf){fig-pos='H'}\n:::\n:::\n\n\n\n\n\n### Advanced Therapies for Ulcerative Colitis\nIn this example, we consider a systematic literature review of Phase 3 \nrandomized controlled trials investigating the following advanced therapies: \ninfliximab, adalimumab, vedolizumab, golimumab, tofacitinib, ustekinumab, \nfilgotinib, ozanimod, and upadacitinib [@panaccione_efficacy_2023]. This review \nincluded 48 RCTs, from which 23 were found eligible for inclusion in a \nnetwork meta-analysis. The included RCT populations were largely comparable in their baseline\ncharacteristics, though some heterogeneity was noted in weight, \ndisease duration, extent of disease, and concomitant medications. \nA risk of bias assessment showed a low risk of bias for all included RCTs, \nwhich were all industry sponsored.\n\nWe here focus on the synthesis of 18 trials that contributed efficacy data for \ninduction in bio-naive populations. The following FDA- and/or EMA-approved \nbiologic or SMD doses were investigated: \n\n* Adalimumab subcutaneous 160 mg at week 0, 80 mg at week 2, and 40 mg at week 4 (`ADA160/80`)\n* Infliximab intravenous 5 mg/kg (`INF5`) at weeks 0, 2, and 6 then every 8 weeks\n* Infliximab intravenous 10 mg/kg (`INF10`) at weeks 0, 2, and 6 then every 8 weeks\n* Filgotinib oral 100 mg once daily (`FIL100`)\n* Filgotinib oral 200 mg once daily (`FIL200`)\n* Golimumab subcutaneous 200 mg at week 0 and 100 mg at week 2 (`GOL200/100`)\n* Ozanimod oral 0.23 mg once daily for 4 days, 0.46 mg once daily for 3 days, then 0.92 mg once daily (`OZA0.92`)\n* Tofacitinib oral 10 mg twice daily for 8 weeks (`TOF10`)\n* Upadacitinib oral 45 mg once daily for 8 weeks (`UPA45`)\n* Ustekinumab intravenous 6 mg/kg at week 0 (`UST6`)\n* Vedolizumab intravenous 300 mg at weeks 0, 2, and 6 (`VED300`)\n\nThe reference treatment is placebo (`PBO`).\n\n\n\n\n::: {.cell tbl-cap='Efficacy outcomes (i.e., clinical remission) data of induction bio-naïve populations' hash='chapter_10_cache/pdf/unnamed-chunk-26_53ec26b3b76be5f0486963ce0d002c70'}\n::: {.cell-output-display}\n\\begin{longtable}{lrrrrrr}\n\\toprule\nstudlab & treat1 & treat2 & event1 & n1 & event2 & n2\\\\\n\\midrule\n\\endfirsthead\n\\multicolumn{7}{@{}l}{\\textit{(continued)}}\\\\\n\\toprule\nstudlab & treat1 & treat2 & event1 & n1 & event2 & n2\\\\\n\\midrule\n\\endhead\n\n\\endfoot\n\\bottomrule\n\\endlastfoot\nACT-1 & INF10 & INF5 & 39 & 122 & 47 & 121\\\\\nACT-1 & INF10 & PBO & 39 & 122 & 18 & 121\\\\\nACT-1 & INF5 & PBO & 47 & 121 & 18 & 121\\\\\nACT-2 & INF10 & INF5 & 33 & 120 & 41 & 121\\\\\nACT-2 & INF10 & PBO & 33 & 120 & 7 & 123\\\\\nACT-2 & INF5 & PBO & 41 & 121 & 7 & 123\\\\\nGEMINI 1 & VED300 & PBO & 30 & 130 & 5 & 76\\\\\nJapic CTI-060298 & INF5 & PBO & 21 & 104 & 11 & 104\\\\\nJiang 2015 & INF5 & PBO & 22 & 41 & 9 & 41\\\\\nM10-447 & ADA160/80 & PBO & 9 & 90 & 11 & 96\\\\\nNCT01551290 & INF5 & PBO & 11 & 50 & 5 & 49\\\\\nNCT02039505 & VED300 & PBO & 22 & 79 & 6 & 41\\\\\nOCTAVE 1 & TOF10 & PBO & 56 & 222 & 9 & 57\\\\\nOCTAVE 2 & TOF10 & PBO & 43 & 195 & 4 & 47\\\\\nPURSUIT-SC & GOL200/100 & PBO & 45 & 253 & 16 & 251\\\\\nSELECTION & FIL100 & FIL200 & 47 & 277 & 60 & 245\\\\\nSELECTION & FIL100 & PBO & 47 & 277 & 17 & 137\\\\\nSELECTION & FIL200 & PBO & 60 & 245 & 17 & 137\\\\\nTRUE NORTH & OZA0.92 & PBO & 66 & 299 & 10 & 151\\\\\nU-ACCOMPLISH & UPA45 & PBO & 54 & 166 & 3 & 81\\\\\nU-ACHIEVE Study 2 & UPA45 & PBO & 41 & 145 & 4 & 72\\\\\nULTRA-1 & ADA160/80 & PBO & 24 & 130 & 12 & 130\\\\\nULTRA-2 & ADA160/80 & PBO & 32 & 150 & 16 & 145\\\\\nUNIFI & UST6 & PBO & 27 & 147 & 15 & 151\\\\*\n\\end{longtable}\n:::\n:::\n\n\n\nThe corresponding network is displayed below:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-27_c01e0a598ab4f9a2e59fa0c88c3a4084'}\n::: {.cell-output-display}\n![Evidence network of 18 trials that contributed efficacy data for induction in bio-naive populations](chapter_10_files/figure-pdf/unnamed-chunk-27-1.pdf)\n:::\n:::\n\n\n\nBelow, we conduct a random effects network meta-analysis of the reported study \neffects (expressed as odds ratio) and consider placebo (`treat = \"PBO\"`) as \nthe control treatment.\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-28_b78022eaac86eb9f9a7383ee4ea0ea9e'}\n\n```{.r .cell-code}\nNMA.uc <- netmeta(TE = TE, seTE = seTE, treat1 = treat1, treat2 = treat2,\n                  studlab = studlab, data = UlcerativeColitis, sm = \"OR\", \n                  ref = \"PBO\", common = FALSE, comb.random = TRUE)\nNMA.uc\n```\n:::\n\n\n\nAll treatments except `FIL100` and `UST6` are significantly more efficacious than `PBO` at inducing clinical remission. We can now estimate the probabilities of each treatment being at each possible rank and the SUCRAs (Surface Under the Cumulative RAnking curve):\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-29_de23198f2b599b78c61126e6235fc1ab'}\n\n```{.r .cell-code}\nsucra.uc <- rankogram(NMA.uc, nsim = 100, random = TRUE, common = FALSE, \n                      small.values = \"undesirable\")\n\n# Exctract the SUCRA values\nsucra.uc$ranking.random\n```\n\n::: {.cell-output .cell-output-stdout}\n```\n ADA160/80     FIL100     FIL200 GOL200/100      INF10       INF5    OZA0.92 \n0.25909091 0.15272727 0.44090909 0.67363636 0.56636364 0.74727273 0.77090909 \n       PBO      TOF10      UPA45       UST6     VED300 \n0.01636364 0.37909091 0.97909091 0.38909091 0.62545455 \n```\n:::\n:::\n\n\n\nThese results indicate that 97.9% of the evaluated treatments are worse than `UPA45`.\n\n\n\n\n\n## Version info {.unnumbered}\nThis chapter was developed using the following version of R and its packages:\n\n\n\n::: {.cell hash='chapter_10_cache/pdf/unnamed-chunk-30_ec881cec5f096cea3eeaeb9cc96563b5'}\n::: {.cell-output .cell-output-stdout}\n```\nR version 4.2.3 (2023-03-15 ucrt)\nPlatform: x86_64-w64-mingw32/x64 (64-bit)\nRunning under: Windows 10 x64 (build 19044)\n\nMatrix products: default\n\nlocale:\n[1] LC_COLLATE=Dutch_Netherlands.utf8  LC_CTYPE=Dutch_Netherlands.utf8   \n[3] LC_MONETARY=Dutch_Netherlands.utf8 LC_NUMERIC=C                      \n[5] LC_TIME=Dutch_Netherlands.utf8    \n\nattached base packages:\n[1] stats     graphics  grDevices utils     datasets  methods   base     \n\nother attached packages:\n[1] dmetar_0.0.9000  netmeta_2.8-2    meta_6.2-1       gemtc_1.0-1     \n[5] coda_0.19-4      dplyr_1.1.1      kableExtra_1.3.4\n\nloaded via a namespace (and not attached):\n [1] httr_1.4.6          magic_1.6-1         jsonlite_1.8.4     \n [4] viridisLite_0.4.2   splines_4.2.3       stats4_4.2.3       \n [7] metafor_4.0-0       slam_0.1-50         yaml_2.3.7         \n[10] robustbase_0.95-1   ggrepel_0.9.3       numDeriv_2016.8-1.1\n[13] pillar_1.9.0        lattice_0.21-8      glue_1.6.2         \n[16] digest_0.6.31       rvest_1.0.3         minqa_1.2.5        \n[19] colorspace_2.1-0    MuMIn_1.47.5        htmltools_0.5.5    \n[22] Matrix_1.5-4        plyr_1.8.8          pkgconfig_2.0.3    \n[25] mvtnorm_1.1-3       Rglpk_0.6-5         scales_1.2.1       \n[28] webshot_0.5.4       svglite_2.1.1       rjags_4-14         \n[31] metadat_1.2-0       lme4_1.1-32         tibble_3.2.1       \n[34] farver_2.1.1        generics_0.1.3      ggplot2_3.4.2      \n[37] withr_2.5.0         nnet_7.3-19         cli_3.6.1          \n[40] magrittr_2.0.3      mclust_6.0.0        evaluate_0.21      \n[43] fansi_1.0.4         nlme_3.1-162        MASS_7.3-58.3      \n[46] truncnorm_1.0-9     forcats_1.0.0       xml2_1.3.3         \n[49] class_7.3-22        tools_4.2.3         lifecycle_1.0.3    \n[52] stringr_1.5.0       kernlab_0.9-32      munsell_0.5.0      \n[55] cluster_2.1.4       fpc_2.2-10          compiler_4.2.3     \n[58] systemfonts_1.0.4   rlang_1.1.0         grid_4.2.3         \n[61] nloptr_2.0.3        rstudioapi_0.14     CompQuadForm_1.4.3 \n[64] igraph_1.4.2        labeling_0.4.2      rmarkdown_2.21     \n[67] boot_1.3-28.1       gtable_0.3.3        codetools_0.2-19   \n[70] abind_1.4-5         flexmix_2.3-19      R6_2.5.1           \n[73] gridExtra_2.3       knitr_1.42          prabclus_2.3-2     \n[76] fastmap_1.1.1       utf8_1.2.3          mathjaxr_1.6-0     \n[79] poibin_1.5          modeltools_0.2-23   stringi_1.7.12     \n[82] parallel_4.2.3      Rcpp_1.0.10         vctrs_0.6.1        \n[85] DEoptimR_1.0-13     tidyselect_1.2.0    xfun_0.39          \n[88] diptest_0.76-0     \n```\n:::\n:::\n\n\n\n## References\n\n\n",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {
      "knitr": [
        "{\"type\":\"list\",\"attributes\":{\"knit_meta_id\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\"]}},\"value\":[{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"booktabs\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"longtable\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"array\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"multirow\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"wrapfig\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"float\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"colortbl\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"pdflscape\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"tabu\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"threeparttable\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"threeparttablex\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"ulem\"]},{\"type\":\"character\",\"attributes\":{},\"value\":[\"normalem\"]},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"makecell\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]},{\"type\":\"list\",\"attributes\":{\"names\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"name\",\"options\",\"extra_lines\"]},\"class\":{\"type\":\"character\",\"attributes\":{},\"value\":[\"latex_dependency\"]}},\"value\":[{\"type\":\"character\",\"attributes\":{},\"value\":[\"xcolor\"]},{\"type\":\"NULL\"},{\"type\":\"NULL\"}]}]}"
      ]
    },
    "preserve": null,
    "postProcess": false
  }
}